Literature DB >> 6540140

Inhibition of cis-diamminedichloroplatinum secretion by the human kidney with probenecid.

C Jacobs, C N Coleman, L Rich, K Hirst, M W Weiner.   

Abstract

The renal handling of cis-diamminedichloroplatinum (CP) was investigated by measuring the renal clearance of creatinine, inulin, and free platinum in ten cancer patients. Free platinum clearances exceeded the glomerular filtration rate in all time periods. For example, at 1 to 2 hr, the mean clearance of free platinum was 224 +/- 32 (S.E.) ml/min compared to a mean creatinine clearance of 94 +/- 15 ml/min or a mean inulin clearance of 94 +/- 17 ml/min (p less than 0.01), indicating secretion of CP or a metabolite. Seven additional cancer patients were treated with probenecid prior to CP. Fractional platinum clearances, calculated as a ratio of free platinum clearance to creatinine clearance, were reduced significantly in the probenecid-treated group (158 +/- 17%) compared to controls (270 +/- 57%) (p less than 0.03). Fractional platinum clearances, calculated as a ratio of free platinum clearance to inulin clearance, were also significantly reduced in the treated group (154 +/- 14%) compared to controls (271 +/- 47%) (p = 0.04). These results suggest that cisplatin is secreted by the human kidney, and this can be inhibited by probenecid. Such maneuvers may be helpful in improving the therapeutic index of this important chemotherapeutic agent.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6540140

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  15 in total

Review 1.  Uptake carriers and oncology drug safety.

Authors:  Jason A Sprowl; Alex Sparreboom
Journal:  Drug Metab Dispos       Date:  2013-12-30       Impact factor: 3.922

Review 2.  Pharmacokinetic drug interactions of commonly used anticancer drugs.

Authors:  F M Balis
Journal:  Clin Pharmacokinet       Date:  1986 May-Jun       Impact factor: 6.447

Review 3.  Renal Drug Transporters and Drug Interactions.

Authors:  Anton Ivanyuk; Françoise Livio; Jérôme Biollaz; Thierry Buclin
Journal:  Clin Pharmacokinet       Date:  2017-08       Impact factor: 6.447

4.  Pharmacokinetics of unchanged carboplatin (CBDCA) in patients with small cell lung carcinoma.

Authors:  P A Reece; J F Bishop; I N Olver; I Stafford; B L Hillcoat; G Morstyn
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

Review 5.  Role of reactive metabolites in the circulation in extrahepatic toxicity.

Authors:  Roy M Irving; Adnan A Elfarra
Journal:  Expert Opin Drug Metab Toxicol       Date:  2012-06-11       Impact factor: 4.481

6.  Pharmacokinetics and plasma protein binding of two platinum cytostatics CHIP and CBDCA in rats.

Authors:  A Láznícková; M Láznícek; J Kvĕtina; J Drobník
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

7.  Calcium blockers enhance cisplatin-induced nephrotoxicity in rats.

Authors:  J Uozumi; T Ueda; T Yasumasu; Y Koikawa; J Kumazawa
Journal:  Int Urol Nephrol       Date:  1992       Impact factor: 2.370

Review 8.  Polymorphic transporters and platinum pharmacodynamics.

Authors:  Jason A Sprowl; Rachel A Ness; Alex Sparreboom
Journal:  Drug Metab Pharmacokinet       Date:  2012-09-18       Impact factor: 3.614

Review 9.  WR2721 as a modulator of cisplatin- and carboplatin-induced side effects in comparison with other chemoprotective agents: a molecular approach.

Authors:  M Treskes; W J van der Vijgh
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

10.  Cisplatin-induced renal injury is independently mediated by OCT2 and p53.

Authors:  Jason A Sprowl; Cynthia S Lancaster; Navjotsingh Pabla; Edwin Hermann; Ashley M Kosloske; Alice A Gibson; Lie Li; Dorothea Zeeh; Eberhard Schlatter; Laura J Janke; Giuliano Ciarimboli; Alex Sparreboom
Journal:  Clin Cancer Res       Date:  2014-06-10       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.